SHU Portfolio – BioLife: The Story Is Even Better Than We Thought
BioLife is a recent addition to the SHU portfolio and one of its highest conviction buys. We were already very positive, but after the Q3CC, we have become more bullish. […]
BioLife is a recent addition to the SHU portfolio and one of its highest conviction buys. We were already very positive, but after the Q3CC, we have become more bullish. […]
The tax cuts produced a boom in economic growth, but the effects look set to peter out. The tax cuts also unleashed some headwinds that could gather force, like rising […]
Cash burn has declined considerably in the quarter and is guided to decline some more, giving the company some more time to turn things around. That doesn’t take away that […]
Lots of new products and customer wins in the quarter don’t yet show up in the figures, as ramping is slow. But this is a matter of time. More wins […]
The shares have fallen well off their post-IPO high, which was a little over the top. Revenue is still growing at triple digit rate, but marketing cost is growing considerably […]
The company’s shares are buffeted by delays in some orders; some fall in the current quarter, some have been postponed to the next fiscal year. The company has important capabilities […]
While the company had a difficult history, the new CEO seems to be making a difference for the better with the company’s finances greatly deleveraged already and growth resuming. The […]
The shares still priced for a crash that still isn’t materializing. On the other hand, there is no conclusive evidence we have passed the worst of the down-cycle either. What […]
The company still manages to grow through headwinds from the mortgage markets, taking market share. The mortgage market is expected to turn in the second half of next year. Their […]
The share price are off by almost two-thirds from their peak earlier in the year on disappointing growth and gross margin compression. But new design wins in the Android space […]